Search Results - "Sy, Marie‐Pierre"

  • Showing 1 - 17 results of 17
Refine Results
  1. 1
  2. 2

    Increasing prevalence of hypertension among HIV-positive and negative adults in Senegal, West Africa, 1994-2015 by Benzekri, Noelle A, Seydi, Moussa, N Doye, Ibrahima, Toure, Macoumba, Sy, Marie Pierre, Kiviat, Nancy B, Sow, Papa Salif, Gottlieb, Geoffrey S, Hawes, Stephen E

    Published in PloS one (31-12-2018)
    “…Non-communicable diseases, including hypertension (HTN), are increasingly recognized as important causes of morbidity and mortality among people living with…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Effect of Human Immunodeficiency Virus Infection on Human Papillomavirus Clearance Among Women in Senegal, West Africa by Li, Zhuochen, Winer, Rachel L, Ba, Selly, Sy, Marie Pierre, Lin, John, Feng, Qinghua, Gottlieb, Geoffrey S, Salif Sow, Papa, Kiviat, Nancy B, Hawes, Stephen E

    Published in The Journal of infectious diseases (26-04-2023)
    “…Abstract Background Persistent infection with high-risk human papillomavirus (HPV) is associated with development of invasive cervical cancer. Methods…”
    Get full text
    Journal Article
  5. 5

    Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants by Smith, Robert A, Raugi, Dana N, Nixon, Robert S, Seydi, Moussa, Margot, Nicolas A, Callebaut, Christian, Gottlieb, Geoffrey S

    Published in The Journal of infectious diseases (15-05-2024)
    “…The activity of lenacapavir against human immunodeficiency virus type 1 (HIV-1) has been extensively evaluated in vitro, but comparable data for human…”
    Get full text
    Journal Article
  6. 6

    Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants by Smith, Robert A, Raugi, Dana N, Wu, Vincent H, Zavala, Christopher G, Song, Jennifer, Diallo, Khardiata Mbaye, Seydi, Moussa, Gottlieb, Geoffrey S

    Published in Antimicrobial agents and chemotherapy (01-05-2019)
    “…We compared the activity of the integrase inhibitor bictegravir against HIV-1 and HIV-2 using a culture-based, single-cycle assay. Values of 50% effective…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9

    HIV-2 Drug Resistance Genotyping from Dried Blood Spots by Raugi, Dana N, Nixon, Robert S, Leong, Sally, Faye, Khadim, Diatta, Jean Phillipe, Sall, Fatima, Smith, Robert A, Sall, ElHadji Ibrahima, Malomar, Jean Jacques, Seydi, Moussa, Gottlieb, Geoffrey S

    Published in Journal of clinical microbiology (17-12-2020)
    “…The treatment of HIV-2 in resource-limited settings (RLS) is complicated by the limited availability of HIV-2-active antiretroviral drugs and inadequate access…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors by Raugi, Dana N, Smith, Robert A, Gottlieb, Geoffrey S

    Published in Journal of virology (15-01-2016)
    “…Protease is essential for retroviral replication, and protease inhibitors (PI) are important for treating HIV infection. HIV-2 exhibits intrinsic resistance to…”
    Get full text
    Journal Article
  12. 12

    The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1 by Smith, Robert A, Raugi, Dana N, Wu, Vincent H, Leong, Sally S, Parker, Kate M, Oakes, Mariah K, Sow, Papa Salif, Ba, Selly, Seydi, Moussa, Gottlieb, Geoffrey S

    Published in Antimicrobial agents and chemotherapy (01-12-2015)
    “…Treatment options for individuals infected with human immunodeficiency virus type 2 (HIV-2) are restricted by the intrinsic resistance of the virus to…”
    Get full text
    Journal Article
  13. 13

    In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2 by Smith, Robert A, Raugi, Dana N, Pan, Charlotte, Sow, Papa Salif, Seydi, Moussa, Mullins, James I, Gottlieb, Geoffrey S

    Published in Retrovirology (05-02-2015)
    “…Dolutegravir recently became the third integrase strand transfer inhibitor (INSTI) approved for use in HIV-1-infected individuals. In contrast to the extensive…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16
  17. 17